Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors

Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res., 74, 2913, 10.1158/0008-5472.CAN-14-0155 Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N. Engl. J. Med., 369, 1691, 10.1056/NEJMoa1304369 Todo, 2001, Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing, Proc. Natl. Acad. Sci. USA, 98, 6396, 10.1073/pnas.101136398 Cheema, 2013, Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model, Proc. Natl. Acad. Sci. USA, 110, 12006, 10.1073/pnas.1307935110 Fukuhara, 2016, Oncolytic virus therapy: a new era of cancer treatment at dawn, Cancer Sci., 107, 1373, 10.1111/cas.13027 Sugawara, 2020, Efficacy of a third-generation oncolytic herpes virus G47Delta in advanced stage models of human gastric cancer, Mol. Ther. Oncolytics, 17, 205, 10.1016/j.omto.2020.03.022 Yamada, 2020, Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation, Mol. Ther. Oncolytics, 18, 535, 10.1016/j.omto.2020.08.010 Uchihashi, 2021, Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis, Mol. Ther. Oncolytics, 22, 388, 10.1016/j.omto.2021.06.008 Sugawara, 2021, Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition through dynamic intratumoral immune modulation, Mol. Ther. Oncolytics, 22, 129, 10.1016/j.omto.2021.05.004 Yajima, 2021, Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma, Mol. Ther. Oncolytics, 23, 402, 10.1016/j.omto.2021.10.012 Todo, 2022, A phase I/II study of triple-mutated oncolytic herpes virus G47Δ in patients with progressive glioblastoma, Nat. Commun., 13, 4119, 10.1038/s41467-022-31262-y Todo, 2022, Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial, Nat. Med., 28, 1630, 10.1038/s41591-022-01897-x Andtbacka, 2015, Talimogene laherparepvec improves durable response rate in patients with advanced melanoma, J. Clin. Oncol., 33, 2780, 10.1200/JCO.2014.58.3377 Desjardins, 2018, Recurrent glioblastoma treated with recombinant poliovirus, N. Engl. J. Med., 379, 150, 10.1056/NEJMoa1716435 Nakao, 2011, A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer, Cancer Gene Ther., 18, 167, 10.1038/cgt.2010.65 Hecht, 2003, A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma, Clin. Cancer Res., 9, 555 Mulvihill, 2001, Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial, Gene Ther., 8, 308, 10.1038/sj.gt.3301398 Jiang, 2016, Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy, Nat. Med., 22, 851, 10.1038/nm.4123 Serrels, 2015, Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity, Cell, 163, 160, 10.1016/j.cell.2015.09.001 Wilky, 2019, Immune checkpoint inhibitors: the linchpins of modern immunotherapy, Immunol. Rev., 290, 6, 10.1111/imr.12766 O'Reilly, 2019, Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial, JAMA Oncol., 5, 1431, 10.1001/jamaoncol.2019.1588 Royal, 2010, Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J. Immunother., 33, 828, 10.1097/CJI.0b013e3181eec14c Renouf, 2022, The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma, Nat. Commun., 13, 5020, 10.1038/s41467-022-32591-8 Weiss, 2018, Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma, Invest. New Drugs, 36, 96, 10.1007/s10637-017-0525-1 Russell, 2018, Oncolytic viruses as antigen-agnostic cancer vaccines, Cancer Cell, 33, 599, 10.1016/j.ccell.2018.03.011 Ijichi, 2006, Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression, Genes Dev., 20, 3147, 10.1101/gad.1475506 Ijichi, 2011, Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma, J. Clin. Invest., 121, 4106, 10.1172/JCI42754 Miyabayashi, 2013, Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals, Cancer Res., 73, 2221, 10.1158/0008-5472.CAN-12-1453 Sano, 2021, Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism, Gut, 70, 1713, 10.1136/gutjnl-2020-320608 Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 Chard, 2015, A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer, Clin. Cancer Res., 21, 405, 10.1158/1078-0432.CCR-14-0464 Rosenberg, 2018, Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response, J. Gastrointest. Oncol., 9, 143, 10.21037/jgo.2018.01.13 Ko, 2016, A phase I study of FOLFIRINOX plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma, Pancreas, 45, 370, 10.1097/MPA.0000000000000458 Hakim, 2019, Why HALO 301 failed and implications for treatment of pancreatic cancer, Pancreas (Fairfax), 3, e1, 10.17140/POJ-3-e010 Pang, 2021, Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy, Molecules, 26, 4250, 10.3390/molecules26144250 Upadhrasta, 2019, Strategies in developing immunotherapy for pancreatic cancer: recognizing and correcting multiple immune "defects" in the tumor microenvironment, J. Clin. Med., 8, 1472, 10.3390/jcm8091472 Pallmer, 2019, NK cells negatively regulate CD8 T cells via natural cytotoxicity receptor (NCR) 1 during LCMV infection, Plos Pathog., 15, e1007725, 10.1371/journal.ppat.1007725 Iraolagoitia, 2016, NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells, J. Immunol., 197, 953, 10.4049/jimmunol.1502291 Sano, 2019, Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment, Oncogenesis, 8, 8, 10.1038/s41389-018-0117-8 Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat. Rev. Cancer, 19, 133, 10.1038/s41568-019-0116-x Ichimaru, 2019, Indirubin 3'-oxime inhibits migration, invasion, and metastasis InVivo in mice bearing spontaneously occurring pancreatic cancer via blocking the RAF/ERK, AKT, and SAPK/JNK pathways, Transl. Oncol., 12, 1574, 10.1016/j.tranon.2019.08.010 Yu, 2001, Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel, Cancer Res., 61, 517 Réjiba, 2009, Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies, Neoplasia, 11, 637, 10.1593/neo.81686 Todo, 1999, Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus, Hum. Gene Ther., 10, 2741, 10.1089/10430349950016483